Literature DB >> 21660639

Does adiponectin upregulation attenuate the severity of acute pancreatitis in obesity?

Hayder H Al-Azzawi1, Kathryn M Ziegler, Deborah A Swartz-Basile, Sue Wang, Henry A Pitt, Nicholas J Zyromski.   

Abstract

INTRODUCTION: Obesity is an independent risk factor for severe acute pancreatitis, though the mechanisms underlying this association are unknown. The powerful anti-inflammatory adipokine adiponectin is decreased in obesity. We recently showed that the severity of pancreatitis in obese mice is inversely related to circulating adiponectin levels, and therefore hypothesized that adiponectin upregulation would attenuate the severity of pancreatitis in obese mice.
METHODS: Forty congenitally obese mice were studied. Seven days prior to study, 20 mice received a single tail vein injection of adenovirus expressing recombinant murine adiponectin (APN; 2 × 10⁸ plaque forming unit (pfu)), and the remainder received a control adenoviral vector expressing β-galactosidase (β-gal; 2 × 10⁸ pfu). Half of the mice in each group had pancreatitis induced by cerulein injection (50 mcg/kg IP hourly for 6 h). The other half received saline on the same schedule. Serum APN concentration and pancreatic tissue concentrations of interleukin (IL)-6, IL-1β, and MCP-1 were measured by ELISA. Histologic pancreatitis score was calculated based on the degree of inflammation (0-4), edema (0-4), and vacuolization (0-4). Data were analyzed by ANOVA and Tukey's tests; p < 0.05 was considered significant.
RESULTS: No difference in body weight was observed between groups. Serum APN was significantly upregulated in the APN group compared with the β-gal group. Pancreatic tissue concentration of IL-6 was significantly decreased in the APN group compared with the β-gal group. No change either in pancreatic tissue concentration of IL-1β and MCP-1 or in the severity of histologic pancreatitis were observed.
CONCLUSION: Adiponectin upregulation modulates the pancreatic cytokine milieu but does not attenuate pancreatitis in this model of mild acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660639     DOI: 10.1007/s11605-011-1583-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  45 in total

1.  Obesity increases the severity of acute pancreatitis: performance of APACHE-O score and correlation with the inflammatory response.

Authors:  Georgios I Papachristou; Dionysios J Papachristou; Haritha Avula; Adam Slivka; David C Whitcomb
Journal:  Pancreatology       Date:  2006-04-19       Impact factor: 3.996

Review 2.  The evolving role of leptin and adiponectin in chronic liver diseases.

Authors:  Emmanuel Tsochatzis; George V Papatheodoridis; Athanasios J Archimandritis
Journal:  Am J Gastroenterol       Date:  2006-09-04       Impact factor: 10.864

3.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

Review 4.  The contribution of adipose tissue and adipokines to inflammation in joint diseases.

Authors:  Eric Toussirot; Gérald Streit; Daniel Wendling
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

5.  Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions.

Authors:  Daiji Kawanami; Koji Maemura; Norihiko Takeda; Tomohiro Harada; Takefumi Nojiri; Yasushi Imai; Ichiro Manabe; Kazunori Utsunomiya; Ryozo Nagai
Journal:  Biochem Biophys Res Commun       Date:  2004-02-06       Impact factor: 3.575

6.  Nuclear magnetic resonance spectroscopy-based metabolomics of the fatty pancreas: implicating fat in pancreatic pathology.

Authors:  Nicholas J Zyromski; Abhishek Mathur; G A Nagana Gowda; Carl Murphy; Deborah A Swartz-Basile; Terence E Wade; Henry A Pitt; Daniel Raftery
Journal:  Pancreatology       Date:  2009-05-19       Impact factor: 3.996

7.  Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis.

Authors:  S-W Lee; J-H Kim; M-C Park; Y-B Park; S-K Lee
Journal:  Scand J Rheumatol       Date:  2008 Jul-Aug       Impact factor: 3.641

8.  Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes.

Authors:  Anna M Wolf; Dominik Wolf; Holger Rumpold; Barbara Enrich; Herbert Tilg
Journal:  Biochem Biophys Res Commun       Date:  2004-10-15       Impact factor: 3.575

Review 9.  Leptin in the regulation of immunity, inflammation, and hematopoiesis.

Authors:  G Fantuzzi; R Faggioni
Journal:  J Leukoc Biol       Date:  2000-10       Impact factor: 4.962

10.  Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism.

Authors:  Liping Qiao; Chenhui Zou; Deneys R van der Westhuyzen; Jianhua Shao
Journal:  Diabetes       Date:  2008-03-28       Impact factor: 9.461

View more
  4 in total

1.  Role of IL-6 in the resolution of pancreatitis in obese mice.

Authors:  Maria Pini; Davina H Rhodes; Karla J Castellanos; Andrew R Hall; Robert J Cabay; Rohini Chennuri; Eileen F Grady; Giamila Fantuzzi
Journal:  J Leukoc Biol       Date:  2012-03-16       Impact factor: 4.962

2.  Therapeutic administration of orlistat, rosiglitazone, or the chemokine receptor antagonist RS102895 fails to improve the severity of acute pancreatitis in obese mice.

Authors:  Elise A Malecki; Karla J Castellanos; Robert J Cabay; Giamila Fantuzzi
Journal:  Pancreas       Date:  2014-08       Impact factor: 3.327

Review 3.  Adiponectin in inflammatory and immune-mediated diseases.

Authors:  Giamila Fantuzzi
Journal:  Cytokine       Date:  2013-07-11       Impact factor: 3.861

4.  Rosiglitazone improves survival and hastens recovery from pancreatic inflammation in obese mice.

Authors:  Maria Pini; Davina H Rhodes; Karla J Castellanos; Robert J Cabay; Eileen F Grady; Giamila Fantuzzi
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.